• Like
현지 참가기업 프로필(120개사)
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

현지 참가기업 프로필(120개사)

  • 3,572 views
Published

 

Published in Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
3,572
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
6
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. BioPartnering North America 2009 참가회사 프로필 요약 Company name: 1 AGILE THERAPEUTICS Website: http://www.agiletherapeutics.com/index.html Contact Person: Jeffrey Frick, Chief Business Officer, (609) 683-1880, ext 153 NJ USA jfrick@agiletherapeutics.com Products and Services: Products and Services: Agile Therapeutics (Agile) is a privately held specialty pharmaceutical company focused on the development of innovative women’s healthcare products. Agile’s franchise strategy is to build a pipeline of innovative, women's health products. The company's lead program is a low-dose, once-weekly contraceptive patch. To date, the Company has raised a total of $35 million in venture funding. Partnering meeting 희망여부 Company name: 2 AIM Therapeutics Inc. Website: http://www.aimtherapeutics.com Contact Person: MaRS Centre, Heritage Building, 101 College Street, Suite 335 Toronto, Ontario, M5G 1L7, Phone: 416.673.8199, Fax: 416.971.7300, info@aimtherapeutics.com Products and Services: Products and Services: AIM Therapeutics is engaged in the discovery and development of breakthrough medical therapies to improve the lives of people with immune and inflammatory disorders. Originally founded in June 2005 as AtheroMedix Inc., the company merged with Salpep Biotechnology Inc. in March 2007 to form AIM Therapeutics Inc. The company’s new name stands for ‘Advanced Immune Modulation’ which more accurately represents our broadened technology platforms. AIM Therapeutics is focused on developing novel treatments for asthma, COPD, bronchitis, spinal cord injury, restenosis, type 1 diabetes and other inflammatory conditions with significant unmet medical needs. Partnering meeting 희망여부 Company name: 3 Akesis Pharmaceuticals, Inc. Website: http://www.akesis.com/ Contact Person: 888 Prospect Street, Suite 320 La Jolla, CA 92037, Tel: 1 888 476 5115, Fax: 1 858 348 2183, Email: info@akesis.com Products and Services: Products and Services: Akesis Pharmaceuticals is a development stage company focused on developing and commercializing breakthrough therapeutics for a broad spectrum of metabolic diseases, including but not limited to diabetes, obesity, and dyslipidemias. Akesis is well positioned with its lead drug candidate, AKP-020, a unique, patent-protected p vanadium-containing product that has been shown to lower blood glucose levels in type 2 diabetes patients. The company also intends to in-license preclinical and clinical stage compounds that have metabolic disease treatment potential. Akesis’ management team is highly experienced in drug development and is leading the company in validating these findings, with the goal of offering unique FDA approved products to treat diabetes and other metabolic diseases that significantly impact public health. Partnering meeting 희망여부 Company name: 4 Alder BioPharmaceuticals Website: http://www.alderbio.com/ Contact Person: 11804 North Creek Parkway South, Bothell, WA 98011. Phone: 425-205-2900 Fax: 425-205-2901. Email: info@alderbio.com Products and Services: Products and Services: Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune 1
  • 2. diseases, and inflammatory diseases. Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying a strategic partner to assist in the development and marketing of its lead antibody product, ALD518, for Rheumatoid Arthritis and Cancer. Partnering meeting 희망여부 Company name: 5 Allergy Therapeutics plc Website: http://www.allergytherapeutics.com/ Contact Person: Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom. Tel +44 (0)1903 844 700 Products and Services: Products and Services: Allergy Therapeutics®. (AT) is a Europe-based specialty pharmaceutical company focused upon the diagnosis and treatment of allergy. AT has an existing sales base of approximately £33.8m/€43m per annum, an MHRA-approved manufacturing capability and an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and once registered could potentially revolutionise the treatment of allergy. Partnering meeting 희망여부 Company name: 6 Alpharma Inc. Website: http://www.alpharma.com/pages/default.aspx Contact Person: 440 Route 22 East, Bridgewater, NJ 08807. (908) 566-3800. Products and Services: Products and Services: Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. With nearly 1,400 employees and 2007 revenues of $722 million, Alpharma is active in more than 80 countries around the world. Founded in Norway in 1903, Alpharma is currently positioned for growth atop two strong businesses: pharmaceutical products (KADIAN® capsules and the FLECTOR® Patch), and animal health. Together, these business units provide operational efficiencies and enable the company to continue to deliver sustainable growth and long-term value. Alpharma has a growing franchise in the U.S. pain market with KADIAN® capsules and the FLECTOR® Patch. Alpharma is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock through its animal-health division. Partnering meeting 희망여부 Company name: 7 Alphora Research Inc. Website: http://www.alphoraresearch.com/ Contact Person: 2395 Speakman Drive, Suite 2001, Mississauga, Ontario Canada L5K 1B3 Tel: 905 403 0477. Fax: 905 403 8744. Email: info@alphoraresearch.com Products and Services: Products and Services: Alphora Research Inc. provides API (Active Pharmaceutical Ingredient) technology development services for the scale up of complex small molecules with pharmaceutical and biotechnological applications. Founded in 2003 by Dr. Jan Oudenes, the company is located in Sheridan Research Park in Mississauga, Ontario, Canada. The location ideally places the 2
  • 3. company within the Pharmaceutical community in Canada and in close proximity to 5 major universities and their associated resources. Alphora's range of services cover the developmental requirements for API's from pre-clinical through to phase III and to the successful technology transfer to manufacturing locations throughout the world. Partnering meeting 희망여부 Company name: 8 Ambit Biosciences Website: http://www.ambitbio.com/ Contact Person: 4215 Sorrento Valley Blvd. San Diego, CA 92121. Tel: 858-334-2100. Fax: 858-334-2199 email: bgiargiari@ambitbio.com. Products and Services: Products and Services: Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small- molecule kinase inhibitors for the treatment of cancer. With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development. And Ambit Biosciences has the technology, the expertise and the vision to succeed in the kinase space. Ambit Biosciences is combining the power of their KINOMEscan™ kinase profiling technology with an innovative licensing strategy and a history of kinase expertise to discover, optimize and advance a sustainable pipeline of small molecule kinase inhibitors for the treatment of cancer. Partnering meeting 희망여부 Company name: 9 Amicus Therapeutics Website: http://www.amicustherapeutics.com/ Contact Person: 6 Cedar Brook Drive, Cranbury, NJ 08512. Tel 609-662-2000. Fax 609-662-2001 Email: info@amicustherapeutics.com Products and Services: Products and Services: Amicus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of a new class of small molecule, orally-administered drugs to treat a range of human genetic diseases. Amicus’ innovative therapies apply to conditions in which crucial proteins are defective as a result of improper folding. Instead of trying to replace these complex proteins, Amicus’ approach uses pharmacological chaperones to selectively bind to the misfolded target protein, increase stability, and help the protein fold into its proper three-dimensional shape. This allows the protein to be trafficked to the specific location in the cell, where it performs its intended biological function. Pharmacological chaperone technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for patients. Partnering meeting 희망여부 Company name: 10 Anapharm Website: http://www.anapharm.com/ Contact Person: 2500, rue Einstein, Québec (Qc Canada G1P 0A2 Phone: (418) 527-4000 Fax: (418) 527-3456. Email: info@anapharm.com Products and Services: Products and Services: Anapharm is an industry leader in early-phase drug 3
  • 4. development, providing a wide range of services to the pharmaceutical, biotechnology, and generic-drug industries. Anapharm offers a vast array of bioanalytical laboratory services, as well as services in Phase I clinical development, bioequivalence, and regulatory affairs. As a PharmaNet Development Group company, Anapharm has access to a global network of resources for Phase I–IV consulting and clinical drug development. Partnering meeting 희망여부 Company name: 11 Apeiron Biologics Website: http://www.apeiron-biologics.com/ Contact Person: Forschungs- und Entwicklungs GmbH, Campus Vienna Biocenter 5, 1030 Vienna, Austria. Tel: +43 (1) 865 65 77. Fax:+43 (1) 865 65 77 – 9280. Email: apeiron@apeiron-biologics.com Products and Services: Products and Services: The company, operational since 2005, was founded by Josef Penninger, the director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA). Based on Josef Penninger's research activities, three projects are currently pursued: APN 01: Development of recombinant human soluble Angiotensin Converting Enzyme 2 as a therapy for the Acute Respiratory Distress Syndrome as well as cardiovascular and kidney diseases. Cbl-b: Shaping of immunoreactivity by molecules inhibiting or enhancing the function of Cbl-b, a critical negative regulator of T-cell activation and autoimmunity. DREAM: Novel approach for pain management by induction of the expression of the endogeneous opioid precursor prodynorphin via interaction with the suppressor protein DREAM. Apeiron's general strategy is to generate value by profiling and developing therapeutics up to a first proof of concept in patients (Phase I / II clinical trials). Following successful proof of concept in patients, the aim is to out-license projects to pharmaceutical companies, enabling the initiation of new R&D projects. Partnering meeting 희망여부 Company name: 12 Apthera, Inc. Website: http://www.apthera.com/ Contact Person: Gail Thurston, Vice President, Corporate Development. Tel: (480) 348-9707 Email: gthurston@apthera.com Products and Services: Products and Services: Apthera, Inc. was founded in July, 2005 to develop and commercialize a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive cancers. Currently, the Company has products in clinical trials aimed at reducing disease recurrence rates for breast and prostate cancers. Apthera licensed its core intellectual property from The University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, TX, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) in Rockville, MD. Apthera recently announced positive Phase I/II clinical trial results for its lead cancer immunotherapy product, NeuVax™ for the treatment of breast cancer. Planning is underway for a large, international, pivotal Phase III clinical trial of NeuVax for the treatment of early-stage (node-positive) HER2-positive breast cancer. Apthera intends to obtain regulatory approval of NeuVax for the treatment of breast cancer in both the U.S. and international markets. Partnering meeting 희망여부 4
  • 5. Company name: 13 Aquinox Pharmaceuticals Inc Website: http://www.aqxpharma.com/ Contact Person: Suite 600 - 555 West 12th Avenue, Vancouver, BC V5Z 3X7 Canada t: 604.629.9223 Email: business@aqxpharma.com Products and Services: Products and Services: Aquinox Pharmaceuticals is a pharmaceutical company committed to the discovery, development, and commercialization of novel and targeted small molecule therapeutics for the treatment of cancer and inflammatory disease. The company was founded in 2004 as a spin-off from research conducted at the University of British Columbia, the BC Cancer Agency and the Vancouver Coastal Health Research Institute, organizations with outstanding reputations for world-class research. The scientific founders of the company discovered a unique biochemical enzyme called SH2-containing inositol 5'-phosphatase (known as SHIP) and drugs to regulate this enzyme. Activation of SHIP inhibits the critical PI3K pathway in blood cells. The PI3K pathway promotes cell growth, proliferation, survival, and immune cell activation. Aquinox's most advanced program is its SHIP activator program and has generated promising data with the highly selective compound AQX-MN100, a potent activator of SHIP. AQX-MN100 possesses many desirable drug properties and has demonstrated potent anti-cancer activity as well as anti-inflammatory activity both in vitro and in vivo. Aquinox is now evaluating AQX-MN100, and several closely related analogs that have properties for different routes of administration, and is poised to complete final preclinical testing and advance its lead product into IND studies. The company's second program is its SHIP inhibition program for blood cell recovery and is making advances in developing drug candidates. Partnering meeting 희망여부 Company name: 14 ARIUS Research Inc. Website: http://www.ariusresearch.com/ Contact Person: 55 York Street, 15th Floor, Toronto, Ontario M5J 1R7. T 416 862 2323. F 416 862 9696. E contact@ariusresearch.com Products and Services: Products and Services: ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. At the core of the Company is our unique, proprietary FunctionFIRST™ technology platform that generates and selects therapeutic antibodies based on their activity. This antibody generation engine has enabled ARIUS to grow a pipeline of more than 400 antibody drug candidates. In addition to the antibodies we are developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. Partnering meeting 희망여부 Company name: 15 Asterand plc Website: http://www.asterand.com/Asterand/ Contact Person: TechOne Suite 501, 440 Burroughs, Detroit, MI 48202-3420 United States. Tel: + 1 (313) 263-0960. Fax: +1 (313) 263.0961. Email: customerservice@asterand.com 5
  • 6. Products and Services: Products and Services: Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Our mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, The company is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. Focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. Partnering meeting 희망여부 Company name: 16 AstraZeneca Website: http://www.astrazeneca.ca/ Contact Person: 1004 Middlegate Road, Mississauga, Ontario Canada L4Y 1M4. Tel: (905) 277-7111 or 1-800-565-5877. Fax: (905) 270-3248. Email: customer.relations1@astrazeneca.com Products and Services: Products and Services: AstraZeneca is one of the largest pharmaceutical companies in the world. Their innovative and extensive product portfolio spans six therapeutic areas: cardiovascular, gastrointestinal, oncology, respiratory, neuroscience and infection. Partnering meeting 희망여부 Company name: 17 Avance Website: N/A Contact Person: N/A Products and Services: N/A Partnering meeting 희망여부 Company name: 18 Avantium Technologies B.V. Website: http://www.avantium.com/ Contact Person: Zekerringstraat 29, 1014 BV Amsterdam, The Nertherlands. Tel: +31 (0)20 586 8080. Fax: +31 (0)20 586 8085. Email: infor@avantium.com Products and Services: Products and Services: Avantium is a leading technology company specialized in advanced high-throughput R&D for application in the energy, chemicals and pharmaceutical industries. The company’s headquarters and laboratories are located in Amsterdam, in the Nertherlands. Avantium’s proprietary high- throughput technology enables a faster and more cost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company’s mission is to increase the success rate and economics of product and process development. Partnering meeting 희망여부 Company name: 19 Bachem AG Website: http://www.bachem.com/ 6
  • 7. Contact Person: 3132 Kashiwa Street Torrance, CA 90505 United States Phone +1 888 422 2436 Fax: +1 310 539 9428 Products and Services: Products and Services: Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides Partnering meeting 희망여부 Company name: 20 Bayer AG Website: http://www.bayer.com/en/homepage.aspx Contact Person: 51368 Leverkusen. Tel: ++49 (0)214 / 30-1 Products and Services: Products and Services: Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer AG defines common values, goals and strategies for the entire Group. The three subgroups and three service companies operate independently, led by the management holding company. The Bayer Group markets some 5,000 products. Best-sellers include: in the health care field: Yasmin®/YAZ®/Yasminelle®, Betaferon®/Betaseron®, Kogenate®, Adalat®, Avalox®/Avelox® Nutrition field: Confidor®/Gaucho®/Admire®/Merit®, Flint®/Stratego®/Sphere® High-tech materials field: Makrolon®, Baydur®, Bayflex® Footwear. Partnering meeting 희망여부 Company name: 21 Bend Research Website: http://www.bendres.com/ Contact Person: Bruce Johnson, Manager, Business Development. Tel: 541-382-4100. Email: johnson@bendres.com Products and Services: Products and Services: Bend Research’s core business is the development of new technologies for the pharmaceutical industry. They began operations in Central Oregon in 1975 and, since that time, have focused on applying fundamental scientific and engineering principles to provide enabling, proprietary technologies to address our clients' needs. Partnering meeting 희망여부 Company name: 22 BioAlberta Website: http://www.bioalberta.com/index.asp Contact Person: 314 Capital Place, 9707-110 Street, Edmonton, AB T5K 2L9 Tel: (780) 425-3804 Fax: (780) 409-9263 Email: info@bioalberta.com Products and Services: Products and Services: BioAlberta is the central voice and the organizing hub for the bioindustry in Alberta, Canada. BioAlberta is a private, not-for-profit industry association, representing Alberta's growing bioindustry. BioAlberta currently lists over 130 members, including producers, users and supporters of biotechnology activities in Alberta. BioAlberta activities are focused in the following areas: Government advocacy, Industry promotion, Increasing industry access to financing, Facilitating access to human resources and Business development and networking opportunities. Alberta's bioindustry is a broad field of endeavour encompassing biotechnology, environmental science, medical technology, industrial bioproducts, agriculture 7
  • 8. biotechnology, bio-informatics and natural health products. Partnering meeting 희망여부 Company name: 23 Biolex Therapeutics Website: http://www.biolex.com/ Contact Person: 158 Credle Street, Pittsboro, NC 27312 USA. Tel: 919.542.9901. Fax: 919.542.9910. Email: bizdev@biolex.com Products and Services: Products and Services: Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a novel technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their lead product candidate, Locteron, is in Phase 2 clinical trials and is the only controlled-release interferon alfa known to us to be currently in active clinical development for the treatment of chronic hepatitis C. Partnering meeting 희망여부 Company name: 24 Bionor Immuno AS Website: http://www.bionorimmuno.com/ Contact Person: Klostergata 33, NO-3732 Skien, Norway, Tel: +47 35 90 85 00. Fax: +47 35 90 85 01. E-mail: info@bionorimmuno.com Products and Services: Products and Services: Bionor Immuno AS was established on July 14th 2000 as a spin off from its sister company, Bionor AS (now Bionor Laboratories AS) that develops peptide-based diagnostics for infectious diseases. Both companies are located at Klosterøya in Skien, Norway together with Bionor Immuno’s development partner Mericon AS. Partnering meeting 희망여부 Company name: 25 Bionovo Website: http://www.bionovo.com/ Contact Person: 5858 Horton Street, Suite 375, Emeryville, CA 94608. Tel: 510-601-2000. Fax: 510-601-5050 Products and Services: Products and Services: Bionovo is a drug discovery and development company focused on developing safe and effective drugs for the treatment of unmet medical needs in women’s health and cancer. Their mission is to improve the quality of women’s health and defeat life-threatening cancers. Partnering meeting 희망여부 Company name: 26 BioWisdom Ltd Website: http://www.biowisdom.com/ Contact Person: Harston Mill, Harston, Cambridge CB22 7GG United Kingdom. Tel: +44 (0)1223 874800. Fax: +44 (0)1223 874801. Tel: 1-978-461-1250. Fax: 1-978-461-1299. Email: info@biowisdom.com Products and Services: Products and Services: BioWisdom develops ontology powered intelligence solutions for the healthcare industry. Their solutions make extensive use of medical labels in all of their forms. From text strings to chemical structures these labels, and the rules that govern the behaviour of the real things behind them, are used to power our technology. Search can be enlightened and results clustered. Information can be annotated and filtered. Data can be formatted and ‘semantically' normalized. Intelligence can be visualized and interrogated. All of BioWisdom's products and services are focused on access, formatting and 8
  • 9. visualization of healthcare intelligence providing unparalleled cognitive reach for individuals, teams and organisations Partnering meeting 희망여부 Company name: 27 Burrill & Company Website: http://www.burrillandco.com/ Contact Person: One Embarcadero Canter Suite 2700, San Francisco, CA 94111. Tel: 415-591-5400. Fax: 415-591-5401. Email: burrill@b-c.com Products and Services: Products and Services: Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $950 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Partnering meeting 희망여부 Company name: 28 Calibrant Biosystems, Inc Website: http://www.calibrant.com/ Contact Person: 910 Clopper Road, Suite 220N Gaithersburg, MD 20878. Tel: (301) 977-7900. Fax (301) 977-7981. Email: info@calibrant.com Products and Services: Products and Services: Calibrant Biosystems, Inc. is a Gaithersburg, Maryland biotechnology company pioneering the discovery of novel protein drug targets and markers for the treatment and diagnosis of disease. Calibrant’s unique approach to protein biomarker discovery applies the proprietary Gemini™ platform to the analysis of microdissected tissue specimens, enabling targeted and comprehensive evaluation of proteins within isolated cells and their local microenvironment. Partners : 1) Leading clinical researchers to develop new first-in-class therapeutics, beginning with the discovery of novel protein drug targets, disease pathways, and biomarkers from microdissected human tissue specimens. With an initial focus in oncology, Calibrant researchers have active development programs in a range of cancer indications including ovarian and primary brain cancer. 2) Pharmaceutical and biotechnology companies seeking to leverage the Gemini™ engine during the drug development process by identifying novel therapeutic targets, reducing drug development times and attrition rates, and developing targeted drugs or repositioning existing compounds on the basis of effective patient stratification. Partnering meeting 희망여부 Company name: 29 Catalent Pharma Solutions, Inc. /Gala Biotech Website: http://www.gala.com/index.html 9
  • 10. Contact Person: 8137 Forsythia Street, PO Box 620160 Middleton, WI 53562. Phone: 608.824.9920. Fax: 608.824.9930. Email: galainfo@catalent.com Products and Services: Products and Services: Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. Partnering meeting 희망여부 Company name: 30 Ceapro Inc. Website: http://www.ceapro.com Contact Person: Suite 4174 Enterprise Square, 10230 Jasper Avenue, Edmonton, Alberta, Canada T5J 4P6. Tel: 780.421.4555. Fax: 780.421.1320. Email: llanuke@ceapro.com Products and Services: Products and Services: Incorporated in 1997, Ceapro's mission is to be a global leader in developing and commercializing products for the human and animal health market through the use of proprietary technology and renewable resources. Ceapro has achieved a reputation as an innovative formulator and advanced processor of active ingredients, botanical extracts, and therapeutic products. They take the best nature has to offer and create ingredients and formulations that lead to the development of effective shampoos, cleansers, moisturizers, and cosmetics - licensed and marketed worldwide. Partnering meeting 희망여부 Company name: 31 Cellzome AG Website: http://www.cellzome.com/index.html Contact Person: Cellzome in Germany, Ms. Hilary Soul, Cellzome AG Meyerhofstrasse 1 69117 Heidelberg, Germany. Tel. +49 (0) 6221 137 57 0. Fax. +49 (0) 6221 137 57 201. Email: info@cellzome.com Products and Services: Products and Services: Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome is applying its distinctive Kinobeads™ technology to the discovery and development of novel, selective, kinase inhibitors targeting key inflammatory mediators in immune receptor signalling and chemotaxis, including PI3Kγ and Zap-70. Partnering meeting 희망여부 Company name: 32 Circassia Website: http://www.circassia.co.uk/ Contact Person: Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA UK. Tel: +44 (0)1865 784574. Fax: +44 (0)1865 784576. All business development opportunities should be directed to Charles Swingland: Email: 10
  • 11. Charlesswingland@circassia.co.uk Products and Services: Products and Services: Circassia is a clinical-stage specialty biopharmaceutical company focused on developing medicines designed to cure allergies, combat organ transplant rejection and speed recovery after major surgery. The Company was initially founded to develop and commercialise a range of allergy therapeutics, based on its proprietary technology, which have the potential to transform current treatment. With its portfolio of allergy products progressing through clinical development, the company has broadened its pipeline into other areas where immune system control is essential. The first of these is organ transplant rejection. Circassia is also developing a critical care therapy that is designed to improve patients’ recovery after a range of surgical operations.The Company is well funded having completed a first round fund raising in January 2007 and a second round in January 2008, and is supported by a syndicate of widely respected institutional and venture capital investors. Partnering meeting 희망여부 Company name: 33 CIRION BioPharma Research Inc. Website: http://www.cirion.com/ Contact Person: 2121 Berlier, Laval, QC H7L 3M9. Tel: 450-682-2231. Fax: 450-902-3060. Email: businessdevelopment@cirion.com Products and Services: Products and Services: CIRION was founded by Dr. Sylvain Desrochers and Dr. Lise Dallaire, high-level researchers with a passion for innovation and research excellence. CIRION now is a leading provider of global central laboratory services and is proud to count some of the world's top 10 biopharmaceutical companies among its clients. CIRION is a knowledge-based, GLP-compliant Central Laboratory dedicated to providing project management services and scientific expertise for Phase I to IV clinical studies. CIRION has developed expertise in the management of complex clinical research projects. Partnering meeting 희망여부 Company name: 34 CoMentis, Inc. Website: http://www.comentis.com/ Contact Person: 280 Utah Avenue, Suite 275, South San Francisco, CA 94080. Phone: 650-869-7600. Fax: 650-869-7626. Email: press@comentis.com Products and Services: Products and Services: CoMentis, Inc. is headquartered in South San Francisco, with research operations in both South San Francisco and Oklahoma City. The company is engaged in the discovery and development of small- molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders. CoMentis currently has three product development programs in its pipeline: ATG-3, a topical (eye drop) anti-angiogenesis compound for neovascular AMD in Phase II development; CTS-21166, an orally active beta-secretase inhibitor for Alzheimer’s disease in Phase I development; and a series of next generation α7 nAChR agonists in preclinical development. Partnering meeting 희망여부 11
  • 12. Company name: 35 Conformetrix Website: http://www.conformetrix.com/index.html Contact Person: Dr. Gordon Barker, Business Development Manager. The Manchester Incubator Building, 48 Grafton Street, Manchester, M13 9XX, UK. Email: contact@conformetrix.com T:+44-(0)161-606-7213. F:+44-(0)161-606-7300. Products and Services: Products and Services: Conformetrix offers a new platform technology that, for the first time, can rapidly determine highly accurate and biologically-relevant (aqueous) 3D and 4D structures of any small soluble molecule. Uniquely, our proprietary method quantifies experimentally the 4D conformational preference (in terms of modality, angle and libration amplitude) of each rotatable bond without recourse to electrostatics or van der Waals calculations. Partnering meeting 희망여부 Company name: 36 Corealis Pharma Inc. Website: http://www.corealispharma.com/ Contact Person: 141, Avenue du Président-Kennedy, Suite SB – 6520 Montréal (Québec) Canada H2X 3Y7 Tel : (514) 987 – 0401. Fax : (514) 987 – 0432. Email: info@corealispharma.com Products and Services: Products and Services: COREALIS Pharma is dedicated to the research and development of pharmaceutical finished solid dosage forms through the use of robust and innovative formulation and process technologies in order to surpass the specific needs of the pharmaceutical industry of today and tomorrow. Partnering meeting 희망여부 Company name: 37 Critical Pharmaceuticals Ltd Website: http://www.criticalpharmaceuticals.com Contact Person: Gareth King, PhD. Chief Business Officer. BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom. Tel: +44 (0)115 8820 100. E- mail: gareth.king@criticalpharmaceuticals.com Products and Services: Products and Services: Critical Pharmaceuticals is a biotechnology company with proprietary drug delivery technologies for injectable sustained release and nasal delivery of challenging drugs including proteins and peptides. Critical Pharmaceuticals are experts in drug delivery and are developing a number of ground breaking products to treat diseases as diverse as growth hormone deficiency and schizophrenia. Critical Pharmaceuticals actively partners its drug delivery technologies and candidate drugs with pharmaceutical and biotechnology companies. For more information, or to discuss a specific opportunity, please contact us. Partnering meeting 희망여부 Company name: 38 CSL Limited Website: N/A Contact Person: Zita Cunningham, Vice President Business Development. Phone: +61 3 9389 1824. Email: bus.dev@csl.com.au address: 45 Poplar Rd, Parkville, Victoria 3052 Australia. Products and Services: Products and Services: The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. They develop and manufacture vaccines and plasma protein biotherapies. These products help treat and prevent serious human medical conditions With major facilities in Australia, Germany, Switzerland and the US, CSL has over 9000 employees working in 27 countries. 12
  • 13. Partnering meeting 희망여부 Company name: 39 CTI Life Sciences Fund Website: http://www.ctisciences.com/english/ Contact Person: Richard J. Meadows, Managing Partner, CTI Life Sciences Fund. 1, Place Ville- Marie, office #1635 Montreal, Quebec, Canada H3B 2B6. Phone: (514) 787-1618. Cell: (514) 826-8326. Fax: (514) 787-1620. E-mail: Products and Services: Products and Services: Based in Montreal, CTI Life Sciences Fund L.P. is a limited partnership formed in 2006. The Fund make venture capital investments in high quality emerging life sciences companies at the start-up and clinical development stage primarily in Canada. This fund is the first of its kind created in Quebec since 2002. CTI Life Sciences Fund L.P. has secured C$100 million in commitments from Quebec, institutional investors such as the Caisse de dépôt et placement du Québec, the Solidarity Fund QFL, FIER Partners L.P. and the Régime de rentes du Mouvement Desjardins and CTI Capital Group’s partners. The CTI Life Sciences Fund L.P. team of professionals in science and finance has extensive experience in the biotechnology and the pharmaceutical industries. The Fund works closely with entrepreneurs and researchers to increase the value of these young companies. Partnering meeting 희망여부 Company name: 40 Curis, Inc Website: http://www.curis.com/index.php Contact Person: 45 Moulton Street, Cambridge, MA 02138. Tel: [617] 503-6500. Fax: [617] 503-6501. Products and Services: Products and Services: Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. Partnering meeting 희망여부 Company name: 41 Cytokinetics, Inc. Website: http://www.cytokinetics.com/ Contact Person: 280 East Grand Avenue, South San Francisco, CA 94080. Tel:(650) 624-3000. Fax: (650) 624-3010. Email: investor@cytokinetics.com Products and Services: Products and Services: Cytokinetics is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas, including cancer and cardiovascular diseases. However, the most important distinguishing feature of Cytokinetics is instead found in their commitment to innovation that has translated their focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs they are 13
  • 14. pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. Partnering meeting 희망여부 Company name: 42 Cytovance Biologics, Inc. Website: http://www.cytovance.com/ Contact Person: 840 Research Parkway, Suite 400, Oklahoma City, OK 73104. Phone: (405) 319-8310. Fax: (405) 319-8339. Email: info@cytovance.com Products and Services: Products and Services: Cytovance Biologics® was founded to help biopharmaceutical companies move recombinant protein and antibody products rapidly from the bench through clinical development. Their unique services couple first-hand client-side experience with technical expertise and operational excellence to efficiently and cost-effectively deliver processes, products and the supporting knowledge necessary to complete clinical development and meet regulatory requirements. They offer a comprehensive range of process development and cGMP manufacturing services conducted in brand new state-of-the-art facilities, plus a portfolio of technical, financial and strategic support services. Partnering meeting 희망여부 Company name: 43 KAI Pharmaceuticals Inc. Website: http://www.kaipharma.com/ Contact Person: Natalie Holles, Vice President, Business Development. Email: partnering@kaipharma.com Address: 270 Littlefield Avenue, South San Francisco, CA 94080. Tel: (650) 244-1100 Products and Services: Products and Services: KAI (kī) Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in cardiovascular disease and pain. Lead product candidate : KAI-9803, is partnered with Bristol-Myers Squibb and has demonstrated efficacy in reducing damage to heart muscle and improving cardiac function in patients with myocardial infarction (MI) who undergo balloon angioplasty. Second clinical program : KAI-1678, is a promising first-in-class drug candidate that may address both the inflammatory and neuropathic pain markets. Third clinical program : KAI-1455, is designed to reduce ischemic injury during planned surgical procedures, such as coronary artery bypass grafting, vascular surgery and pediatric cardiac surgery. KAI’s expertise is in the selective modulation of intracellular protein:protein interactions via delivery of peptide drugs into the cell. The Company has applied 14
  • 15. its core technology to discover highly potent and selective inhibitors and activators for validated members of the protein kinase C (PKC) family of isozymes. This approach has demonstrated therapeutic potential clinically and in many preclinical disease models Partnering meeting 희망여부 Company name: 44 JERINI AG Website: http://www.jerini.com/cms/en/home.php Contact Person: Jerini AG Invalidenstrasse, 130 10115 Berlin Germany. T +49-30-978 93-0 F +49-30-978 93-105. Email: info@jerini.com Products and Services: Products and Services: Jerini is a pharmaceutical company focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with partners. Partnering meeting 희망여부 Company name: 45 Intas Biopharmaceuticals Ltd Website: http://www.intasbiopharma.co.in/ Contact Person: Plot No. 423 / P / A/ GIDC, Sarkhej - Bavla Highway, Moraiya, Taluka - Sanand, 382 210. Ahmedabad, Gujarat, India. Tel: +91 - 2717 - 660100/01. Fax : +91 - 2717 – 251189. Email: business@intasbiopharma.co.in contract.services@intasbiopharma.co.in Products and Services: Products and Services: Intas Biopharmaceuticals, Ltd. develops and markets biopharmaceutical products. Its products include rHu G-CSF that is used clinically for prevention and treatment of chemotherapy-induced neutropenia; and rHu EPO, which is used clinically for prevention and treatment of chemotherapy-induced neutropenia and renal failure. The company also offers oncology products, such as Cytax, Gemibine, Carbopa, Zodox, and Bical; Redemide, Arsenox, Arasid, Dabaz, Merex, Hyras, and Intalfa; and Neukine, Zolasta, Itaspor, and Clogen. In addition, Intas Biopharmaceuticals provides contract research and manufacturing services for bulk biopharmaceuticals and finished formulations. Partnering meeting 희망여부 Company name: 46 Inovio Biomedical Corp. Website: http://www.genetronics.com/ Contact Person: Dr. Michael Fons, Vice-President, Corporate Development. Phone: 858-410-3122. Address: Corporate Headquarters, Inovio Biomedical Corporation, 11494 Sorrento Valley Rd. San Diego, CA USA 92121-1318. Phone: 858-597-6006. Fax: 858-597-0451 Products and Services: Products and Services: Inovio Biomedical Corporation (AMEX: INO) is focused on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases. Successful development of this new generation of vaccines — DNA vaccines — has been hindered by the lack of safe, efficient and cost effective DNA delivery methods capable of enabling their potency. Inovio's electroporation-based DNA delivery technology has shown potential to play a pivotal role in facilitating delivery and enhancing the potency of preventive and therapeutic vaccines. 15
  • 16. Inovio is a leader in developing DNA delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable dramatically increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then "express" the proteins it was encoded to produce. These proteins, or antigens, are designed to be uniquely associated with a targeted cancer or infectious disease, and may then stimulate a more powerful immune response if the immune system encounters the targeted disease at a subsequent time. Partners : Targeting diseases with significant unmet treatment needs, including cancers and chronic infectious diseases such as HIV and hepatitis C virus, creating products combining DNA-based immunotherapies or DNA vaccines with Inovio's delivery platform. Partnering meeting 희망여부 Company name: 47 InNexus Biotechnology Inc. Website: http://www.ixsbio.com/about.html Contact Person: Kathy Flint, Tel: (480) 862-7500. Address: 1055 West Hastings Street, Ste 2200 Vancouver, British Columbia Canada V6E 2E9. Tel:1-480-862-7500. Products and Services: Products and Services: Antibodies and Monoclonal Antibodies Antibodies are produced naturally within the body and attack (bind with) diseased cells and either weaken or destroy them, allowing a person to recover from an infection. Monoclonal Antibody technology allows one to isolate and expand individual antibodies for the treatment of numerous diseases, including Cancer. Monoclonal Antibodies display qualities unlike any other drug yet discovered in that they are very specific (good at targeting ) and relatively non toxic; however, of the thousands of monoclonal antibodies developed to date only a relative few have been approved by the FDA as drugs. Most have failed to become approved drugs because of a lack of potency. InNexus Dynamic Cross Linking (DXL™) Antibody Platform is a drug modification approach that adds secondary properties to monoclonal antibodies (binding is a primary property) and applies to virtually every antibody product currently in development. Adding these secondary properties can increase the potency of antibodies or add new properties. As an example, InNexus utilized DXL™ with a humanized monoclonal antibody, licensed by the FDA for the treatment of non-Hodgkin’s, B-Cell lymphoma. DXL™ greatly enhanced the killing of cancer cells in culture by this antibody, dramatically increasing its potential potency. Partnering meeting 희망여부 Company name: 48 Innate Pharma Website: http://www.innate-pharma.com/major.html Contact Person: Grand Pre 121 Ancien Chemin De Cassis Marseille, 13009 France. Phone: 33 4 96 19 05 58. 16
  • 17. Products and Services: Products and Services: Now in clinical phase, Innate Pharma is developing three product platforms that target three classes of innate immune receptors: Tγδ and NK cell receptors known as receptors of "non-conventional lymphocytes", and Toll family receptors, expressed by dendritic cells and, for part of them, by certain classes of cancer cells. Each platform benefits from either direct or indirect validation of efficacy in various clinical settings, confirming the potential of this approach developed by Innate Pharma. Partnering meeting 희망여부 Company name: 49 Inimex Pharmaceuticals, Inc. Website: http://www.inimexpharma.com/ Contact Person: Inimex Pharmaceuticals Inc. 8540 Baxter Place Burnaby, B.C. Canada V5A 4T8. Tel: (604) 225-2251. Fax: (604) 225-2257. Email: info@inimexpharma.com Products and Services: Products and Services: Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will significantly reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. (1) IDR product IMX942) targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin- resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. (2) IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms. The scientific background on IDR-1, a prototype IDR compound, was recently published in the journal Nature Biotechnology (Nat. Biotech. Vol. 25 No. 4) Partnering meeting 희망여부 Company name: 50 ImmunoVaccine Technologies Inc. Website: http://www.immunovaccine.com/ Contact Person: 1819 Granville Street, Suite 303 Halifax, Nova Scotia, B3J 3R1. Tel: (902) 492-1819. Fax (902) 492-0888. Email: info@immunovaccine.com Products and Services: Products and Services: ImmunoVaccine Technologies Inc. (IVT) is a clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. IVT is commercializing breakthrough vaccines developed through the combination of 17
  • 18. the VacciMax® platform, a vaccine delivery and enhancement system and a large selection of validated vaccine antigens. The VacciMax® platform is able to stimulate an earlier, more powerful, long lasting antibody and cellular immune response. IVT is also able to reduce the number of doses required for protection against infectious diseases like influenza. IVT has completed the scale-up and manufacturing method development for the VacciMax® platform. The company is conducting a Phase 1 clinical trial of IMT 1012, a therapeutic breast and ovarian cancer vaccine and is planning to begin a second Phase 1 for a therapeutic prostate cancer vaccine in early 2009. Partnering meeting 희망여부 Company name: 51 iCo Therapeutics Inc. Website: http://www.icotherapeutics.com/ Contact Person: John G. Clement Ph.D. Chief Technical officer, Chief Development Officer 777 Hornby Street Vancouver, British Columbia V6Z 1S4 Canada. Phone: 604-602-9414 Products and Services: Products and Services: iCo Therapeutics, Inc., a development stage specialty pharmaceutical company, focuses on reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. It has three compounds under development, including iCo-007, an anti-sense molecule, which is in Phase I clinical trial for diabetic macular edema; iCo-008, a monoclonal antibody to take into a Phase II clinical trial for allergic conjunctivitis; and iCo-009, an experimental oral formulation of Amphotericin B, which is at a pre-clinical stage. Partnering meeting 희망여부 Company name: 52 Farris, Vaughan, Wills & Murphy Barristers Website: http://www.farris.com/default.aspx Contact Person: 25th Floor 700 W Georgia Street, Vancouver, BC Canada V7Y 1B3. Tel: 604 684 9151. Fax: 604 661 9349. Email: info@farris.com Products and Services: Products and Services: Farris is a leading Canadian law firm with offices in Vancouver, Kelowna and Victoria, British Columbia. For over 100 years, Farris has provided innovative & practical solutions, timely and efficient service and a breadth and depth of knowledge and experience in all areas of the law to a diverse client base including some of the largest public institutions and private corporations. Many of our lawyers have been recognized as leaders in their field. A number of our practitioners are acknowledged in the Canadian Legal Lexpert Directory and many are ranked among the top 500 leading lawyers in Canada. In addition, we are the top corporate and litigation law firm in Vancouver, according to Lexpert. We offer a complete range of legal services including corporate and commercial; securities; banking; real estate; technology; biotechnology; litigation and labour 18
  • 19. law. Partnering meeting 희망여부 Company name: 53 Solicitors Website: N/A Contact Person: registrations@solicitors.com Products and Services: Products and Services: Solocitor is a world-wide law firm and offers variety of legal services Partnering meeting 희망여부 Company name: 54 Halozyme Therapeutics, Inc. Website: http://www.halozyme.com/ Contact Person: 11388 Sorrento Valley Road, San Diego, CA 92121. Phone: 858.794.8889 Fax: 858.704.8311. Email: info@halozyme.com Products and Services: Products and Services: Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase® and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need. Partnering meeting 희망여부 Company name: 55 Genome British Columbia Website: http://www.genomebc.ca/aboutus/default.htm Contact Person: 500-555 West 8th Avenue, Vancouver, BC V5Z 1C6 Phone: (604) 738-8072 Products and Services: Products and Services: Genome British Columbia is a research organization that invests in and manages large-scale genomics and proteomics research projects and science and technology platforms focused on areas of strategic importance such as human health, forestry, fisheries, ethics, agriculture and the environment. By working collaboratively with all levels of government, universities and industry, Genome BC is the catalyst for a vibrant, genomics- driven life sciences cluster with far reaching social and economic benefits for the province and Canada. Genome BC's major investors are Genome Canada and the Province of British Columbia. This funding is complemented by other private and public investments. Partnering meeting 희망여부 Company name: 56 Gail Rudakewich Biomedical Animation 19
  • 20. Website: http://synapse-visuals.com/gail.htm Contact Person: Gail Rudakewich, Tel: 416 453 3304. Email: gail@synapse-visuals.com Products and Services: Products and Services: Gail Rudakewich is a biomedical animation and illustration company that offers creative artistic skills to communicate complex medical and scientific ideas in a dynamic visual form. Gail produces 3D animations and illustrations that accurately convey a client’s vision. Gail’s clientele is varied and includes medical science professionals from hospitals and academic institutions, and companies in the biotechnology & pharmaceuticals industry. Partnering meeting 희망여부 Company name: 57 Eurand International S.p.A. Website: http://www.eurand.com/ Contact Person: Via Martin Luther King, 13 20060, Pessano con Bornago Milan. Tel: +39-02-95428-1. Fax: +39-02-9574-5012. Email: bizdev@eurand.com Products and Services: Products and Services: Via Martin Luther King has leveraged our proprietary drug delivery technologies to develop a diverse product portfolio in a range of therapeutic areas. Their current product portfolio includes their own proprietary pharmaceutical products, co-development programs, and products that are enhanced versions of existing drugs available for licensing. Whether developed in-house or in conjunction with a valued client, their pharmaceutical products are a testament to the innovation and broad application of our technologies. Currently, more than 40 products using our technologies are commercialized worldwide. In 2005, they received approval in the United States for an ANDA version of a marketed drug. In early 2007, they completed two phase III trials for a life-saving product that is used in the treatment of Exocrine Pancreatic Insufficiency, a disease often associated with cystic fibrosis and chronic pancreatitis, among others. Partnering meeting 희망여부 Company name: 58 Ergomed GmbH Website: http://www.ergomed-cro.com/ Contact Person: Frankfurt Biotechnology Innovation Centre, Altenhöferallee 3 D-60438 Frankfurt am Main. Tel: +49 (0) 69 / 95 11 74 – 0. Fax: +49 (0) 69 / 95 11 74 – 71. Email: wenke.moeller-hoehne@ergomed-cro.com Products and Services: Products and Services: The ERGOMED Group is a pan-European Clinical Development Company, providing full clinical trial-related services to developers of medical drugs. ERGOMED can assist with strategic clinical development planning, individual study design, project management and monitoring, study site management, drug safety monitoring and pharmacovigilance, medical writing as well as data management, biostatistics, regulatory assistance and other services. In addition, ERGOMED has access to its own Phase 1 unit for healthy volunteer studies as well as those in special populations and early phase oncology studies. With its headquarters in Frankfurt, Germany, and five operational centres in London, Zagreb, Novi Sad, Krakow, and San Antonio ERGOMED currently 20
  • 21. conducts operations in over 20 different European countries. ERGOMED specializes in the fields of Oncology/Hematology and Neurology, with added strengths in Endocrinology and Immunology. while retaining experience in many other therapeutic areas and indications. ERGOMED provides clinical development services to some of the world’s largest pharmaceutical companies as well as to many small- and mid-sized drug development companies and has been responsible for the pivotal studies of several drugs including a number of oncologics which have gone on to receive European regulatory approval. ERGOMED’s success is due largely to its motivated, highly trained, experienced and dedicated workforce. Partnering meeting 희망여부 Company name: 59 Karo Bio AB (Swedish company) Website: http://www.karobio.com/en/ Contact Person: Carl-Magnus Andersson, VP, Discovery Research, Sweden, discovery@karobio.se Products and Services: Drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. Holding strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis, dislipidemia. Undertaking two clinical and four preclinical projects. Announced that an Estrogen receptor compound discovered as part of its research collaboration with Merk & Co., Inc. (Entered Phase I clinical development) Target market : Holding innovative compounds for cardiovascular disease, diabetes and depression areas. Karo Bo will seek a partner to bring eprotirome through phase III clinical trials and to the market The aim is to initiate a collaboration after completion of Phaswe IIb clinical trials. Partnering meeting 희망여부 Company name: 60 Leukemia & Lymphoma Society Website: http://www.leukemia-lymphoma.org/all_chap Contact Person: THE WESTERN CANADA CHAPTER 310-1682 West 7th Avenue Vancouver, BC V6J 4S6 (604) 733-2873 (866) 547-5433 (Toll Free) (604) 733-2848 (Fax) Products and Services: The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The mission of LLS is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million for research specifically targeting blood cancers. The Leukemia & Lymphoma Society's Home Office is based in White Plains, NY. 21
  • 22. Some Home Office staff are also based at regional offices in Alexandria and Cincinnati. Partnering meeting 희망여부 Company name: 61 Medical College of WI Research Foundation Website: http://toolkit.wi.gov/education.htm Contact Person: Dr. Joseph Hill Phone : 414-456-4381 jhill@mcw.edu. The MCW Research Foundation links business with the research capabilities, technology license opportunities, and clinical trial services of the Milwaukee- based Medical College of Wisconsin, which has an annual R&D budget of $120 million. The research foundation is also launching a technology-transfer fund. Partnering meeting 희망여부 Company name: 62 Meditrina Pharmaceuticals, Inc. Website: http://www.meditrina.com/ Contact Person: 300N Fifth Avenue, Suite 150 Ann Arbor, MI USA 48104 (734) 926-0966 Products and Services: Meditrina Pharmaceuticals, Inc. identifies and repurposes already marketed therapies and product candidates at advanced stages of development for new indications focused on improving women’s health disorders with unmet medical needs. The Company’s initial focus includes gynecologic and aromatase- meditated conditions such as endometrial thinning prior to hysteroscopic procedures including endometrial ablations, ectopic pregnancies, endometriosis and uterine fibroids. Meditrina is currently conducting phase II clinical trials with Femathina™ (MPI-674) towards improving outcomes for women who undergo endometrial ablations to treat abnormal uterine bleeding (AUB). MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile that Meditrina is repurposing to improve patient outcomes for this indication. Currently used for the chronic treatment of estrogen-dependent breast cancer in postmenopausal women, AIs are being investigated in a variety of women’s health conditions. Meditrina holds the exclusive worldwide rights to patent applications covering several uses of AIs in gynecologic indications. Partnering meeting 희망여부 Company name: 63 MedPharm Ltd Website: http://www.medpharm.co.uk/ Contact Person: Mr. Paul Barrett Head of Business Development Surrey Research Park United Kingdom 44 (0)1483 457580 Products and Services: MedPharm is a private drug delivery and contract service company committed to the creation and development of novel systems, particularly for topical drug formulations for delivery to the skin, nail, mucous membranes, eye, nose and 22
  • 23. lung. Success reputation with formulating difficult compounds especially in the area of topical drug delivery. With over 100 customers worldwide, MedPharm offers a unique and highly specialized service in pharmaceutical contract research and development, and expert project management from feasibility tests, dosage design and optimization, to preparation of GMP clinical supplies trials and preclinical (GLP and non-GLP) and clinical evaluation. MedPharm has a substantial patent portfolio of novel drug delivery systems. These technologies are available as part of service offering or as stand-alone licenses to third parties. Partnering meeting 희망여부 Company name: 64 Merck & Co., Inc. Website: http://www.merck.com/pubs/ Contact Person: New Jersey, USA Phone: 908-423-1000 Products and Services: Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Partnering meeting 희망여부 Company name: 65 metanomics GmbH Website: http://www.metanomics.de/aboutus.html Contact Person: Berlin Germany, Phone: +49 30 348 07 - 0 company.info@metanomics.de Products and Services: Founded in July 1998 as a joint venture between the BASF AG and a group of scientific staff at the Max-Planck-Institute of Molecular Plant Physiology. is currently tailoring some 2500qm of lab and office space for company specific requirements. is organized into four technical centres; genomics, plant production, bio-analytics and bio-informatics. In addition to the company internal agenda in the area of functional genomics metanomics is keen to engage in further partnerships in all four of technical centers. Partnering meeting 희망여부 Company name: 66 MiCardia Corporation Website: http://www.micardia.com/ Contact Person: Irvine California USA info@micardia.com Tel: +1.949.951.4888 Fax: +1.949.951.4812 Products and Services: MiCardia Corporation is an early stage venture dedicated to designing, developing and commercializing minimally invasive methods to treat heart valve disease – Mitral Valve Regurgitation (MR), Tricuspid Valve Regurgitation and Congestive Heart Failure (CHF). 23
  • 24. the company has built an experienced technical and clinical team, while creating a comprehensive intellectual property portfolio. Proof of concept has been completed for a Dynamically Activated Annuloplasty Ring with novel methods for off-pump intra-operative and chronic percutaneous activation methods. MiCardia has developed an array of advanced annuloplasty rings which may be adjusted dynamically after they are surgically placed in either the mitral valve annulus and/or tricuspid valve annulus position(s). The technology allows changes to the shape and the size of the annuloplasty ring while viewing the modifications in real time via echo (ultrasound), without requiring additional invasive surgery. Partnering meeting 희망여부 Company name: 67 Micromet GmbH Website: http://www.micromet.de Contact Person: HQ: Bethesda MD USA Munich Germany Phone: +49 (0) 89 895277-0 Products and Services: Listed on NASDAQ Market : Cancer, inflammation, autoimmune diseases Current partner: MedImmune, Merck Serono, Morphotek, Nycomed, Tracon Pharmaceuticals Micromet's goal : To build a well-staged pipeline of highly differentiated products for the treatment of cancer, inflammation and autoimmune disease. All drug candidates are derived from antibodies. Technology : BiTE Antibody Platform http://www.micromet.de/index.php?id=124 – Clinical and Preclinical Pipeline overview Partnering meeting 희망여부 Company name: 68 Modigene Inc. Website: http://www.modigeneinc.com/ Contact Person: Israel Phone: 866-644-7811 Fax: +(972)-8-9300091 info@modigeneinc.com Products and Services: Modigene is a biopharmaceutical company utilizing patented technology to develop longer-lasting, proprietary versions of already approved therapeutic proteins that currently generate billions in annual global sales. Technology : Modigene`s core technology is the use of a short, naturally 24
  • 25. occurring amino acid sequence (ctp) to slow the removal of therapeutic proteins from the body without increasing toxicity or altering the oberall biological activity. Product : Human Growth Hormone, Erythropoietin, Interferon B Future Products : Dramatically reduce the number of interventions required to achieve the same therapeutic effect from the same dosage; e.g. reduce the number of injections needed from a daily schedule to weekly. Gain extended patent protection as proprietary new formulations of existing therapies; Achieve faster commercialization with lower risks and costs than those typically associated with a new therapeutic protein; and Be manufactured using industry standard biotechnology based protein production processes. Interested in licensing out : Modigene is pursuing licensing deals with biotechnology companies that have a strategic interest in using our solution to develop longer-lasting versions of their existing therapeutic proteins or peptides. Partnering meeting 희망여부 Company name: 69 Nektar Therapeutics Website: http://www.nektar.com/wt/home/index Contact Person: HQ in San Diego CA, USA, Alabama, India partnerships@nektar.com Products and Services: Nektar developing our own high-value, proprietary products as well as highly differentiated products in partnership with leading pharmaceutical and biotechnology companies. Nektar development programs focus on products that fill unmet needs in diabetes, infectious disease, oncology, and eventually other areas, where they can have significant impact As the product portfolio and pipeline continue to grow, so does the company capacity for innovation. Nektar continues to expand worldwide capabilities, explore new opportunities, and bring fresh perspectives to medicine. Pipeline overview : http://www.nektar.com/wt/page/detailed_pipeline 25
  • 26. Drug Development Platform (Interested in licensing out) : Nektar’s proprietary technologies have the potential to increase significantly the therapeutic value of medicines by enhancing drug performance, increasing patient acceptance, improving patient outcomes, and redefining disease management. These technologies are the foundation of our proprietary products and are made available to our pharmaceutical and biotechnology partners. Partnering meeting 희망여부 Company name: 70 Nerites Corporation Website: http://www.nerites.com/ Contact Person: HQ: Madison, WI USA Phone: 608-443-2440 Email: nerites@nerites.com Products and Services: Product : Medical devices to aid tissue repair speed surgical times, and reduce postoperative complications. Nerites portfolio of surgical adhesive and coating products can be used to : Close internal tears and volds, Affix synthetic and biologic devices, prevent bacterial biofilm formation and postsurgical adhesions, immobilize local therapeutics. Technology : Nerites™ was inspired by marine mussels and the remarkable substance they secrete to bond to underwater surfaces. Nerites scientists create synthetic mimetics of these proteins and use them to build adhesive polymers that can be tailored to fit a broad variety of indications. Products are typically delivered in situ as a hydrogel, liquid, or spray, or they can be pre- coated onto an adjunctive medical device. The innovation and subsequent applications are thoroughly patent-protected. Interests : To seeks corporate partners for specific medical indications. Partnering meeting 희망여부 Company name: 71 Neurobiological Technologies Inc. Website: http://www.ntii.com/ Contact Person: Emeryvill, CA Telephone: (510) 595-6000 Products and Services: A biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. Interests : Licensing In - The company employs a strategy of in-licensing late- stage CNS agents and pursues regulatory approval and commercialization either independently or with a strategic partner. 26
  • 27. Product : NAMENDA® (memantine hydrochloride) received approval for the treatment of Alzheimer's disease in Europe in 2002 and in the U.S. in 2003. In the U.S., NAMENDA is currently being sold by Forest Laboratories for moderate- to-severe Alzheimer's disease. In Europe, memantine has been marketed by Merz & Co. for a number of indications for several years. For Alzheimer's disease, memantine is now being sold by Merz's European marketing partner H. Lundbeck. Under an exclusive marketing agreement, the company will receive royalty payments by Merz and its marketing partners from sales of memantine for Alzheimer's disease. Marketed : Memantine (Moderate-to-Severe Dementia and Alzheimer’s Disease Phase III : VIPRINEX (Acute Ischemic Stroke) XERECEPT ( bAgent being investigated for the treatment of brain swelling associated with brain tumors) Partnering meeting 희망여부 Company name: 72 Neuroimage Inc Website: http://neuroimageinc.com/ Contact Person: Ontario, Canada. Dr. Adolfo Cotter, President / Senior consultant T) 416-457-5699 Products and Services: Components : 1) An ongoing consulting business focused on brain imaging and other areas of neuroscience, 2) Self-directed research and development into the brain-mind interface Service : Image Acquisition (in collaboration with Douglas Hospital affiliated with McGill University Brain imaging processing and analysis (statistical data), Biostatistics, preclinical pathology studies R&D : Research to discover more about the biological basis of cognition. Interests : To explore the market opportunities on the followings; 1) Creative machines (Machine to produce ideas that will complement and enhance the brain’s ability to be creative. 2) Neuroinformatics (combination of information technology and brain discovery indifferent domains (data mining, thought and mood processes) Partnering meeting 희망여부 Company name: 73 NextGen Sciences Website: http://www.nextgensciences.com/ 27
  • 28. Contact Person: Ann Arbor Michigan 48108 t: +1-866-973-7914 (toll free) info@nextgensciences.com Products and Services: Service : NextGen Sciences, located in Ann Arbor, MI, offers a suite of biomarker services for research and development called biomarkerexpress™. The development of protein biomarker assays has been a bottleneck in the drug development pipeline for years. biomarkerexpress™ services utilize proprietary methods to significantly decrease timelines and increase the traditionally low success rates associated with the various stages of biomarker development. These services include: 1. discoveryexpress™ - the discovery of new biomarkers from biological samples (differentially expressed proteins) 2. assayexpress™ - the development of peptide MRM (pMRM) assay to quantitate proteins in biological samples 3. testingexpress™ - the testing of biological or clinical samples to quantify the proteins in the pMRM assays developed in assayexpress™ 4. biomarkerlibrary™ - a biomarker knowledgebase to aid researchers and clinicians in selecting the best biomarkers for each R&D program. Partnering meeting 희망여부 Company name: 74 NextPharma Technologies Website: http://www.nextpharma.com/ Contact Person: North America Mr. Rich Koch T) +1-847-382 5803 Email: rich.koch(at)nextpharma-us.com Products and Services: NextPharma is one of the leading contract manufacturers in Europe for the pharmaceutical, biotechnology and health care industries. Service : Technology service on Product development, manufacturing and packaging, cold chain & logistics. (Analytics, Microbiological testing, clinical trials services) Having separate production units for cephalosporins, penicillins and cytostatics. Solutions such as sustained release and time release formulations/pellets as well as ampoules and effervescent tablets, conventional dosage forms such as tablets, capsules, sugar coated tablets, dry syrups, sachets, ointments and liquids. Partnering meeting 희망여부 Company name: 75 Novacta Biosystems Limited Website: http://www.novactabio.com/ Contact Person: BioPark Hertfordshir, UK Dr. Georg Buchner MBA - VP of Corporate and Business Development Tel:+44 (0)1707 356130 +44 Fax:(0)1707 356131 28
  • 29. mail@novactabio.com Products and Services: Novacta Biosystems is now focussed solely on offering ‘fee for service' activities to blue chip drug development and biofuel companies. Novacta is providing solutions for chemical challenges using Metabolite Factory Technology, biocatalysis capabilities and pathway engineering in bacteria, algae and yeast. Service : Spun out from GloxoSmithKline’s Biotransformation and Natural product chemistry center in 2003. Technology : Biocatalysis use the selective catalytic power of our proprietary collection of enzymes and micro-organisms under mild conditions. It can improve the economic and environmental impact of chemical syntheses and processes. Partnering meeting 희망여부 Company name: 76 Numerate, Inc. Website: http://www.numerate.com/ Contact Person: San Bruno CA USA T) +1 (650) 472 0632 info@numerate.com Mr. Kevin Kaster Business Development Products and Services: Service : Drug Engineering Process (two key breakthroughs): Accurately predicting the activity, ADME and toxicity of small molecule drugs. Numerate has invented machine learning algorithms to deal with the noise and biased nature of biological data to build models that are as accurate as laboratory assays. Numerate models are ligand-based and therefore do not require the crystal structure of the target protein. Numerate models are also applicable to metabolism, PK, and certain safety-related issues. (Generating and searching) (Validation : successfully applied to several therapeutic programs) Partnering meeting 희망여부 Company name: 77 OncoGeneX Technologies Inc. Website: http://www.oncogenex.ca/ Contact Person: Canadian Headquarters : Vancouver, British Columbia Canada Telephone: (604) 736-3678 Fax: (604) 736-3687 Dr. Martin Gleave MD, Chief Scientific Officer Products and Services: A biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. 29
  • 30. Product Pipeline : OncoGenex currently has five product candidates in development: OGX-011 (five Phase 2 clinical trials, completed patient enrollment) In July 2008, reached an agreement with US FDA on the design of a Phase 3 registration trial via SPA process, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development. http://www.oncogenex.com/products/index.html Partnering meeting 희망여부 Company name: 78 Oncolytics Biotech Inc. Website: http://www.oncolyticsbiotech.com/ Contact Person: Mr. Nick Hurst The Equicom Group Calgary, Alberta Tel:403.538.4845 nhurst@equicomgroup.com Products and Services: Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. Headquartered in Calgary, Alberta, Canada, the Company was formed in 1998 to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. Product: The Company’s technologies are based on discoveries made in the 1990s in the Department of Microbiology and Infectious Diseases at the University of Calgary. The potential products are being developed using the naturally occurring reovirus for treatment of cancers in humans. Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are susceptible to reovirus infection and eventual cell death. Progeny virus particles are then able to infect and kill surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available. Oncolytics has discovered that tumour antigens generated by this viral oncolysis may educate the immune system to recognize and kill tumour cells. Oncolytics' clinical program includes human trials using REOLYSIN® alone and in combination with radiation and chemotherapy. Partnering meeting 희망여부 Company name: 79 Orcrist Bio Inc. Website: http://www.orcristbio.com/ Contact Person: Calgary, AB CANADA Tel: (403) 984-3882 Email: andrew@orcristbio.com Products and Services: Orcrist Bio Inc. is a biotechnology company dedicated to developing and 30
  • 31. commercializing promising therapeutics. Located in Calgary, Alberta. Product : Orcrist Bio Inc’s lead program Orcrist’s lead program centers on HYC750, an exciting candidate drug for treating a serious and common side- effect of chemotherapy treatment for cancer - suppression of the patients' white blood cell production. Interests : The company is actively looking to add to its pipeline through in- licensing opportunities. White blood cell depletion is a multi-billion dollar market, and initial research has shown that HYC750 has the potential to be a more effective, safe and affordable alternative to current commercially available mobilizers. The company is currently pursuing a co-development agreement with a US-based stem cell company actively working with complimentary technology to evaluate HYC750’s efficacy in this indication. Partnering meeting 희망여부 Company name: 80 Outsourcing Clinical Trials Website: http://www.out-clinicaltrials.com/ Contact Person: 8/2 Bolshaya Moskovskaya Str., Suite 4-1, St.Petersburg, 191002, Russia Business Development Manager: Ms. Alexandra Zaichenko Phone: +7 812 449 86 34 Email: info@out-clinicaltrials.com Products and Services: OUTSOURCING CLINICAL TRIALS (OCT) is a contract research organization (CRO) with head office in St. Petersburg, Russia. The company provides services to Pharmaceutical, Biotech, and Nutraceutical companies interested in conducting clinical trials in Eastern and Central Europe with 7 offices in Russia, Ukraine, Baltic States, Bulgaria, Belarus, US and free-lance presence in Austria, Czech, Costa Rica, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland, Slovakia, others. Service : High quality data/services Clinical trial services Partnering meeting 희망여부 Company name: 81 Penn Pharmaceuticals Website: http://www.pennpharm.co.uk/ Contact Person: Corporate Headquarters : Gwent, South Wales, UK Telephone: +44 (0) 1495 711222 Email: enquires@pennpharm.co.uk 31
  • 32. Products and Services: Service: A suite of drug development, clinical trial supply and consultancy services enables us to offer a fully integrated and personal service to our clients. - Formulation development, Analytical development, clinical trial packing and labeling, storage & distribution, CMC Consultancy services, Qualified Person Release services Technologies & Capabilities : Facilities & Equipment, High Containment processing, Paediatric formulation & manufacture, Semi-solids form expertise Partnering meeting 희망여부 Company name: 82 Pfizer Inc Website: http://www.pfizer.com/home/ Contact Person: New York, NY 10017 USA Phone: 1-212-733-2323 Products and Services: Pfizer is the world's largest research-based biomedical and pharmaceutical company. Major research and development locations in the United States and England. Recent innovations include Sutent®—a novel cancer medicine that both cuts off the blood supply that feeds tumors and destroys cellular reproduction, and Chantix™—a new prescription medicine and accompanying support plan designed specifically to help smokers quit. In 2007, Pfizer earned $48.4 billion in revenues and invested $8.1 billion in research and development. Partnering meeting 희망여부 Company name: 83 Pharmatek Laboratories, Inc. Website: http://www.pharmatek.com/ Contact Person: San Diego, California 92121 T) 1-858-805-6383 Products and Services: A pharmaceutical chemistry development organization supporting the pharmaceutical and biotechnology industries. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, ICH stability storage and testing, and high- potent & cytotoxic development and manufacturing. Product : Pharmatek Laboratories' Hot Rod Chemistry® (HRC) is a formulation screening kit designed to solubilize drug candidate compounds and prepare them for testing in animal models. Each HRC® kit contains eight non-toxic, orally available formulations that increase the solubility, bioavailability and stability of drug candidates. Each formulation has been created using functional excipients that are GRAS and can be found in FDA approved therapeutics. Partnering meeting 희망여부 Company name: 84 Piramal Healthcare Website: http://www.npilpharma.com/ 32
  • 33. Contact Person: Head office : Mumbai, India Tel: +91-022-3046 6660 US office : Edison New Jersey Tel : +1( 732) 549 9451 Products and Services: Pharma Solutions is one of the very few Contract Manufacturing Organizations (CMOs) that can provide end-to-end support for bringing a drug to market or managing the life cycle of a launched drug. Service : Clinical Phase API synthesis and Formulations Development services and scale up to Commercial API and Finished Dosage form supply. Process Development, synthesis and scale-up of API for Clinical phase studies Commercial manufacturing of APIs at global network of facilities spread across India, UK and North America Drug development services including preformulations studies, formulations development, CTM supply, clinical packaging & distribution and clinical trials at in-house CROs Commercial manufacturing of finished dosage forms (including hormonal products) across global network of sites Partnering meeting 희망여부 Company name: 85 Priaxon Website: http://www.priaxon.com/content/home/index.php Contact Person: Munich Germany Tel.: +49 (0) 89 / 4521308-0 contact@priaxon.com Products and Services: Priaxon opens up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. Technology : design and prediction tools: Proprietary algorithms superior in speed and accuracy for design, similarity and property prediction within very large chemical space. Priaxon uses this integrated technology as a service provider in collaborations with customers reaching from regional biotech companies up to big pharma. Service : Integrated approach, MCR, Chemoinformatics, Drug discovery, D Therapeutic programs, Chemistry services Partnering meeting 희망여부 Company name: 86 Prince Edward Island Business Development Website: http://www.peibusinessdevelopment.com/ 33
  • 34. Contact Person: N/A Products and Services: The Government of Prince Edward Island for the economic development Partnering meeting 희망여부 Company name: 87 Procter & Gamble Website: http://www.pg.com/en_US/index.shtml https://secure3.verticali.net/pg- connection-portal/ctx/noauth/0_0_1_4_83_4_13.do Contact Person: N/A Products and Services: P&G Needs posted on the web site Partnering meeting 희망여부 Company name: 88 ProPharma Partners International Inc. Website: http://www.propharmaipartners.com/ Contact Person: N/A Products and Services: N/A Partnering meeting 희망여부 Company name: 89 Protalix Biotherapeutics Ltd Website: http://www.protalix.com/ Contact Person: Mr. Yossi Maimon, CFO, Israel. T: +972-4-902-8100, Extension 143 E: ir@protalix.com Products and Services: A biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on Protalix proprietary ProCellEx™ protein expression system. Using our ProCellEx™ system Protalix is developing a pipeline of proprietary recombinant therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Technology : Procellex Platform technology, Protein production Protalix's novel bioreactor plant cell system, based on disposable plastic vials Product : Glucocerebrosidase Pipeline Product : ProCellEx™ protein expression system, with an emphasis on treatments. The company identified several product candidates oriented towards specialty disease and therapeutic market segments, including treatments for Fabry disease and female infertility. The company plans to file an investigational new drug application (IND) with the FDA with respect to at least one additional product during 2008. In addition, we are developing a new method for delivering active recombinant proteins systemically through oral administration of transgenic plant cells expressing such biotherapeutic proteins. PRX-102, PRX-111, Acetylcholinesterase Partnership and licensing In addition to our main line of therapeutic products, 34
  • 35. we also rely on partnership opportunities and licensing agreements to develop and maintain our competitive position. We are currently partnered with several world-renowned pharmaceutical companies and leading scientific institutions. Research undertaken to evaluate the potential for the developed acetylcholinesterase and its variants, for various therapeutic fields. To date, our in vitro experiments have shown that the acetylcholinesterase expressed in our ProCellEx™ expression system demonstrates promising biological activity on biochemical and cellular levels. Partnering meeting 희망여부 Company name: 90 Protein Forest, Inc. Website: http://www.proteinforest.com/ Contact Person: Lexington MA USA Phone: 617-926-4778 Email: info@proteinforest.com Products and Services: Protein Forest, Inc. (founded in 2002) is a proteomics tools company. The company develops, manufactures and markets instruments, consumables and software products to scientists around the world. Product : The initial product lines utilize a new technology called parallel isoelectric focusing which is incorporated into the digital ProteomeChip™ (dPC™). The first applications addressed are Mass Spectroscopy (MS) sample prep and Western Blotting. The digital ProteomeChip™ product line brings unmatched speed, reproducibility and high resolution in an easy to use format. The company also develops and markets data analysis software called Mass Spec Results Analysis Tools (MSRAT™) that allows scientists of any discipline to discover the richness of their dPC™ results within minutes. Future applications of the technology include isoelectric protein purification, automated systems and 2D dPC™ formats. U.S Patent 7,166,202 is issued for the dPC™ platform. Protein Forest® is dedicated to the development, manufacture and marketing of leading-edge products to boost the researcher's ability to correlate protein expression, post-translational modifications Technology : The dPC™ Fractionation Technology The dPC™ separates complex biological samples into fractions suitable for mass 35
  • 36. spectroscopy, chromatography and blotting using the principle of parallel isoelectric focusing. Partnering meeting 희망여부 Company name: 91 Proteos, Inc. Website: http://www.proteos.net/ Contact Person: Kalamazoo, MI 49008 T) 269.372.3423 businessdevel@proteos.net Products and Services: Specialized in protein production, expression and purification Service : Protein expression, Protein purification, Peptide Service Product : Proteos now provides crystallographic grade recombinant human renin. As a major supplier of recombinant human renin, Proteos is providing highly purified and characterized enzyme to customers all over the world. (Recombinant Human Renin, Recombinant Human Prorenin, Recombinant Human Renin C-terminal hexa-His tag, Recombinant Human Prorenin C-terminal hexa-His tag, recombinant Human BACE Expertised in the production of highly pure BACE (beta-site APP cleaving enzyme) from E. coli for crystallography. Partnering meeting 희망여부 Company name: 92 PRUDENTAS LLC Website: http://www.prudentas.com/ Contact Person: Moscow, Russia Tel. +7 495 628 3802 contact@prudentas.com Products and Services: PRUDENTAS is a Contract Research Organization (Limited Liability Company) registered in March 2007. Expertise : Pharmaceutical companies and CROs covers the successful conduct of large-scale studies in multiple centers in Russia, Ukraine and Baltic States. Extensive experience in conducting Phases Ib-IV clinical trials for different groups of patients (adults, children) in various therapeutic areas: Current clinical trials in patients with: Severe COPD (Phase II); Renal Cell Carcinoma (Phase IIIb); HIV (Phase II); Crohn Disease (Phase II) ; Hemophilia (Phase Ib) ; Multiple Sclerosis (Phase IV) Cardiovascular (Phase IV) Service : Phase I – IV trials in Russia and Ukraine: Regulatory support of the study, clinical trial monitoring, GCP Auditing, GVCP training for investigators, Medical monitoring, site management, Partnering meeting 희망여부 Company name: 93 QSV Biologics Ltd. Website: http://www.qsvbiologics.com/ 36
  • 37. Contact Person: Edmonton, Alberta, Canada Phone: (780) 438-5722 info@qsvbiologics.com Products and Services: QSV Biologics provides dedicated biopharmaceutical contract manufacturing services for process development & scale-up, pre-clinical research, Phase I, II and III clinical trial and commercial materials to biopharmaceutical firms developing protein therapeutic products. QSV was issued a Health Canada Commercial Establishment License in 2006. Service : Process Development, Pre-clinical manufacturing, GMP Manufacturing, Quality Assurance, Quality Control Partnering meeting 희망여부 Company name: 94 Rules-Based Medicine, Inc. Website: http://www.rulesbasedmedicine.com/ Contact Person: Austin, TX USA info@rbmmaps.com Phone 512-835-8026 Products and Services: Biomarker testing laboratory delivering reproducible, quantitative, multiplexed immunoassay data. The company provides comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. Product & Service : The company uses Multi-Analyte Profiles (MAPs) to measure from several to hundreds of proteins in a small sample. Simply send us acceptable samples (see under "How to Order and Ship") for either HumanMAP or RodentMAP analysis and the company will send you the data in about two weeks. For either MAP, we measure all of the analytes found in the quantitative antigen panel. MAP analysis, data mining Partnering meeting 희망여부 Company name: 95 Sandoz International GmbH Website: http://www.sandoz.com/site/en/index.shtml Contact Person: Products and Services: Sandoz makes over 5,000 different doses of generic pharmaceuticals and biotechnological drugs. As the generics arm of Swiss drug firm Novartis AG, Sandoz develops products including antibiotics and hormone therapies, as well as treatments for cardiovascular, central nervous system, and gastrointestinal disorders. Sandoz produces finished dosage forms of such off-patent drugs as Duragesic (Fentanyl) and GERD drug Prilosec. It also develops active pharmaceutical ingredients used by other companies to form finished products. Beyond the more common tablet form generics, Sandoz manufactures more complex generics in different delivery systems including patches and inhalers. Partnering meeting 희망여부 Company name: 96 Selvita sp. z o.o. Website: http://www.selvita.com/ Contact Person: Poland Phone: +48 12 410 73 80 selvita@selvita.com Products and Services: Selvita is a product and solution provider for the pharmaceutical and biotechnology industry. We deliver comprehensive solutions to the customers from pharma & biotech industry targeted at lowering the cost of introducing innovative therapeutical compounds to the market... 37
  • 38. Service : Drug discovery(custom in silico library construction), Drug targeting & reposition, Chemical synthesis (contract synthesis and syntheses paths optimization), IT for research Protein modeling platform, research project up to the pre-clinical stage. (oncology, central nervous system, infections and diagnostics) Compound : SEL73 program, SEL92 program Needs : compound with hypotensive activity available for partnering Partnering meeting 희망여부 Company name: 97 SemBioSys Genetics Inc. Website: http://www.sembiosys.ca/ Contact Person: Calgary AB, Canada. Partnership Inquiries: Mr. Phillip Stephan Phone: 403.250.5424 Email: stephanp@sembiosys.com Products and Services: SemBioSys Genetics Inc. is a plant biotechnology company with a powerful technology that enables production of high-value pharmaceutical and non- pharmaceutical products in an affordable and sustainable manner. (production solution for drugs needed in large quantities) Product and Service : Plant technology can be applied to a wide variety of product opportunities - including pharmaceutical (insulin for diabetes, Apo AI and Apo AIMilano cardiovascular disease.) and non-pharmaceutical (personal care producers, nutritional oils (omega fatty acids) for use in a variety of consumer goods, and applications for agricultural biotechnology.) Goal : As SemBioSys pharmaceutical products become partnered, the company will work towards identifying new products for our pipeline. Partnering meeting 희망여부 Company name: 98 Signum Biosciences Inc. Website: http://www.signumbiosciences.com/ Contact Person: NJ USA Phone) 732.329.6344 Email: info@signumbio.com Products and Services: Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and certain skin conditions. Signum is focused on therapeutics that are well protected by intellectual property and are developing them for indications that can be commercialized in the near term. 38
  • 39. Interests : Expect to out-license Signum products to both skin care and pharmaceutical companies. Platform : G-protein-mediated signaling, protein phosphorvlation. Pipeline : Focuses on the regulation of cellular signaling networks to develop proprietary molecules to compensate for signaling imbalances that diminish health and cause disease. Signum is commercializing high value cosmetic ingredients and nutritional supplements as well as pharma candidates for major diseases. http://www.signumbiosciences.com/pipeline.html Partnering meeting 희망여부 Company name: 99 Silence Therapeutics AG Website: http://www.silence-therapeutics.com/ Contact Person: Berlin Germany, Chief Scientific Officer Klaus Giese +49 30 9489 2800 Products and Services: RNAi therapeutics in Europe. The company has proprietary short interfering RNA (“siRNA”) molecules. Proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseasede tissues and cells in the body, whilst increasing their bioavilability and circulation times. R&D collaboration with Astra Zneca to develop AtuRNAi against five specific targets including those in respiratory indications. Technology : considered one of the most exciting and significant medical breakthroughs of recent years. RNAi offers the potential for the development of novel therapeutics that silence specific genes involved in the initiation or progression of any disease or disease process Generated revenues of more than Euro 20M in collaboration with the major customers. Partnering meeting 희망여부 Company name: 100 Stem Cell Therapeutics Corp. Website: http://www.stemcellthera.com/ Contact Person: Calgary, AB 403-245-5495 Products and Services: Canadian public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. Product portfolio : NTx™-265, to treat acute stroke and secondary programs, NTx™ 428 for traumatic brain injusry and NTx ™ 488 for multiple sclerosis. Therapeutic approach is to enhandce the body’s inherent self-repair ability. Partnering meeting 희망여부 39
  • 40. Company name: 101 Stromedix, Inc. MA U.S.A Website: http://www.stromedix.com/ Contact Person: Cambridge MA 02141 tel 617.674.8400 info@stromedix.com Products and Services: Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. STX-100 is Stromedix’ first clinical candidate and is being developed for the treatment of chronic allograft dysfunction in kidney transplant recipients. STX-100antifibre activity in pre-clinical models of lung, kidney, liver disease Partnering meeting 희망여부 Company name: 102 Summit plc U.K. Website: http://www.summitplc.com/ Contact Person: Oxfordshire OX UK Tel: +44 (0) 1235 44 39 39 info@summitplc.com Products and Services: Summit plc is a leading UK biotechnology company that is focused on discovering and developing proprietary new drugs to treat serious diseases where there is currently a high and unmet medical need Pharmaceutical & Biotechnology. Technology : Carbohydrate chemistry -Naturally occurring source of new drugs. An emerging technology. Zebrafish biology - Accelerates the drug discovery process, Reduces the attrition rate, Reduces the development costs Partnering meeting 희망여부 Company name: 103 SuperGen Inc. Website: http://www.supergen.com/ Contact Person: Timothy L. Enns Sr. Vice President, Dublin Bld. Dublin CA Ph)925-560-0100 tenns@supergen.com Products and Services SuperGen boasts a development pipeline of several promising compound classes at various stages of development with good drug like properties, ensuring a steady flow of novel therapeutics into the clinic. http://www.supergen.com/subpages/prod-dev.asp Product : Abstract 532 EORTC-NCI-AACR 2006 c-MET Inhibition Radiosensitizes Melanoma by Inhibiting Double Strand DNA Repair. Abstract 1540 AACR 2007 Annual Meeting MP470.HCL, a Potent Suppressor of Rad51, Improves Bioavailability and Tolerability Abstract 4028 MP470 a potent suppressor of Rad51, improves response to platinum-based anticancer agents. Abstract 5421, Abstract 1026, Abstract 671, Abstract 4083, Partnering meeting 희망여부 40
  • 41. Company name: 104 SuppreMol GmbH Website: http://www.suppremol.com/ Contact Person: Martinsried/Munchen Germany Tel: +49 (0)89 30 90 50 680 Email: info@suppremol.com Products and Services: Company is focused on the development of soluble Fcγ-Receptors (sFcRs) which are recombinant autologous therapeutic proteins endowed with a proven strong immunosuppressive potential http://www.suppremol.com/technology.php SuppreMol is developing soluble Fcγ-receptors (sFcRs) for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The most advanced program is an sFcR for ITP. SuppreMol will also develop this sFcR for SLE and RA. In addition the Company promotes an Anti-FcγRIIb monoclonal antibody to target FcRs for therapeutic interventions in autoimmune diseases. Partnering meeting 희망여부 Company name: 105 Synapse Visuals Website: http://www.synapse-visuals.com/ Contact Person: M.Gail Rudalkewich gail@synapse-visuals.com Products and Services: Synapse Visuals have the knowledge and the insight to develop creative and effective solutions for slide show or power point presentation, web site or interactive CD-ROM program, academic publication, brochure or poster. Partnering meeting 희망여부 Company name: 106 Technology Vision Group LLC Website: http://www.techvision.com Contact Person: CA USA Phone: +1.831.464.4230 Products and Services Technology Vision Group LLC (TVG) is a leading life science business development company. Since 1992, TVG has been developing innovative methods to help life science companies attract partners and investors, acquire new products and technologies, and achieve a variety of strategic business development goals. Partnering meeting 희망여부 Company name: 107 TGen Drug Development Services Website: http://www.td2.org Contact Person: Tara Monteleone (Arizona USA) Manager, Business Development 41
  • 42. Phone (602) 358-8322 tmonteleone@tgen.org Products and Services TGen Drug Development Services (TD2) offers cost-reduction programs through advanced technology and economies-of-scale, along with comprehensive billing to accommodate your budget parameters. Partnering meeting 희망여부 Company name: 108 Transcept Pharmaceuticals Website: http://www.transcept.com Contact Person: Richmond, CA 94804 Phone: 510.215.3500 Products and Services A specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. Product : Intermezzo- low dose zdpidem for middle of the night awakening Partnering meeting 희망여부 Company name: 109 TVG LLC Website: http://www.tvg-llc.com Contact Person: Chicago USA support@biopartnering.com Products and Services Technology Vision Group LLC (TVG), organizer of the 7th Annual BioPartnering Europe (BPE) conference for life science companies, announces the extension of support available to delegates Partnering meeting 희망여부 Company name: 110 University of Manitoba Website: http://umanitoba.ca/ Contact Person: Winnipeg, MB R3E 0T6 Tel: (204) 789-3375 E-mail: reshsc@ms.umanitoba.ca Products and Services N/A Partnering meeting 희망여부 Company name: 111 Vakzine Projekt Management GmbH (VPM) Website: http://www.vakzine-manager.de Contact Person: Hannover Germany Tel.: +49 (0) 511 - 169 908-0 42
  • 43. Products and Services A private vaccine and biopharmaceutical development company with a high potential for value creation. Pipeline : Phase II trial successfully completed: VPM4001: allogeneic therapeutic Prostate Cancer vaccine based on irradiated transfected LNCaP cells, producing IL-2 and IFN-y. Preclinical projects: VPM5001: Soluferon®, a second generation ß-interferon for treatment for Multiple Sclerosis has a high potential to be developed for treatment of viral infections VPM1002: prophylactic Tuberculosis vaccine based on live recombinant M. bovis BCG (rBCGΔureC-Hly) producing lysteriolysin for improved antigen presentation VPM2001: prophylactic vaccine against Human Cytomegalo Virus (HCMV) using HCMV “dense bodies” as antigens VPM1001: prophylactic Malaria vaccine based on adjuvanted full size MSP-1 (merozoite surface protein) from Plasmodium falciparum Partnering meeting 희망여부 Company name: 112 Victory Pharma Website: http:// www.victorypharma.com Contact Person: partnering@vicorypharma.com California USA Products and Services Victory markets its pain management products to orthopedists, rheumatologists, pain specialists and selected primary care physicians. At Victory, our experienced sales representatives use their expert knowledge of pain and related conditions as a resource to support healthcare professionals in tailoring pain solutions to the needs of individual patients. NAPRELAN, XODOL, FEXMID 7.5mg, DOLGIC Plus Partnering meeting 희망여부 Company name: 113 VLST Corp Website: http://www.vlstcorp.com Contact Person: Ron Myers (Seattle USA) VP Legal Affairs & Intellectual Property bd@vlstcorp.com Products and Services Product Candidates : VLST-007 43
  • 44. VLST-007 addresses primary mechanisms of immune complexes and macrophage/granulocyte activation that are not currently addressed by existing therapeutics. Preclinical studies of VLST-007 have demonstrated the ability of this therapeutic candidate to inhibit cytokine secretion from activated human dendtiric cells. It has also shown positive effect on joint histopathology compared to control. The demonstration that VLST-007 can modulate immune-complex mediated inflammation is significant because: Potential clinical applications for VLST-007 include rheumatoid arthritis, SLE, sjogren's syndrome, clomerulonephritis, vasculitides, cryoglobulenemia, ITP and AIHA Partnering meeting 희망여부 Company name: 114 Vyteris Website: http://www.vyteris.com Contact Person: investorrelations@vyteris.com (NJ USA) Products and Services Product : LidoSite® – The first FDA-approved pre-filed active anesthetic patch. Now available nation-wide in doctors’ offices, LidoSite® (Lidocaine HCl/ Epinephrine Topical Iontophoretic Patch) 10%/0.1% — Vyteris’ revolutionary active patch — provides fast, effective analgesia prior to blood draws, venipunctures, and other superficial dermatological procedures.1,2 A quick, noninvasive ten-minute application delivers lidocaine, a trusted anesthetic, deep into the skin, significantly reducing the pain of needles.1,2 Partnering meeting 희망여부 Company name: 115 Washington Research Foundation Website: http://www.wrfseattle.org Contact Person: WRF Venture Center Seattle, WA 98102 Tel: (206) 336-5600 Mr. Morgan Hellar WRF Venture Center Manager morgan@wrfcapital.com Products and Services Washington Research Foundation (WRF) helps Washington State research institutions capture value from their emerging technologies through intellectual property management and start-up investment activities. From its licensing successes, WRF built a seed venture fund, WRF Capital, to invest in local private technology companies. WRF Capital's gains are used to support research and entrepreneurship at Washington State research institutions. 44
  • 45. The Washington Research Foundation negotiates license agreements with interested companies capable of commercializing technologies emerging from research institutions in Washington State Partnering meeting 희망여부 Company name: 116 Welichem Biotech Inc. Website: http://www.welichem.com/ Contact Person: busdev@welichem.com BC Canada Products and Services Product : Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, Welichem plans to complete all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In our pipeline, WBI-1001 related proprietary compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. On-going project : Atopic dermatitis, Psoriasis, cander, WBI-1001 autoimmune/inflammatory skin diseases, such as psoriasis and eczema. Partnering meeting 희망여부 Company name: 117 Wolters Kluwer Health Website: http://www.wkhealth.com Contact Person: PA USA N/A Products and Services A leading provider of information for professionals and students in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Professionals and students have long relied on our textbooks, reference products, and journals. Wolters Kluwer Health’s bibliographic, reference and pharmaceutical databases, drug information software, point-of-care tools, web- based information systems and online continuing education products also support the delivery of health information via interactive formats. Partnering meeting 희망여부 45
  • 46. Company name: 118 Xenome Ltd Website: http://www.xenome.com/ Contact Person: Anthony Filippis - VP, Business Development (Australia) email: anthony.filippis@xenome.com ph: +61 7 3720 8055 Products and Services Xenome is a biotechnology company focused on the discovery and development of prptidu-based therapeutics. Synthetic analogs of venom peptides are highly prospective for rapid drug discovery and development, as their bioactive constituents have been designed under selective pressure and perfected by evolution to be inherently specific, potent and stable. Discovery platform : comprises a robust package of venom peptide intellectual property, resources and expertise established to mine the evolutionary advantages inherent in venom peptides and translate them into therapeutic candidates. Compound :Xenome has developed two key compound libraries to underpin its discovery activities, xdiscover™ and xventure™ . Both libraries are novel and proprietary, and are formatted for efficient target screening and SAR. Partnering Interests : An essential component of Xenomecorporate strategy. We are committed to identifying the best partners for our suite of products and technologies. • Territorial/worldwide rights for the further development of Xen2174, our lead product for severe pain, which is currently in Phase II clinical trials • Accessing our unique, venom-based peptide libraries (xdiscover™ and xventure™) for screening against therapeutic targets of interest • Out-licensing IND-ready peptide drug candidates • In addition, Xenome’s discovery and development capabilities are underpinned by its expertise in peptide chemistry and its understanding of the process for developing peptide drugs. Partnering meeting 희망여부 Company name: 119 YM BioSciences Inc. 46
  • 47. Website: http://www.ymbiosciences.com Contact Person: ir@ymbiosciences.com Products and Services YM BioSciences is a therapeutic product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. Product: Two late-stage products: • Nimotuzumab: an anti-cancer antibody in development in various tumor types and approved in several major markets. • AeroLEF®: a proprietary, inhaled-delivery composition of fentanyl for the treatment of moderate to severe acute pain. http://www.ymbiosciences.com/products/index.php Partnering meeting 희망여부 Company name: 120 Zymeworks Website: http://zymeworks.com/ Contact Person: info@zymeworks.com Products and Services Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop industrial enzymes and protein therapeutics Zymeworks’ core business focus is to develop a pipeline of enabling enzymes for the chemical industry and protein therapeutics for the pharmaceutical industry Partnering meeting 희망여부 47